Last quarter (Q3 2023), Traws Pharma's total revenue was $57.00K, a decrease of 0.00% from the same quarter last year. In Q3, Traws Pharma's net income was $-4.74M. See Traws Pharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ 226.00K	$ 226.00K	$ 226.00K	$ 231.00K	$ 2.18M	$ 1.23M
Cost of Revenue	-	-	-	-	-	-
Gross Profit	$ 226.00K	$ 226.00K	$ 226.00K	-	-	-
Operating Expense	$ 10.22M	$ -19.85M	$ -16.72M	$ 25.22M	$ 23.88M	$ 24.51M
Operating Income	$ -21.57M	$ -19.63M	$ -16.50M	$ -24.99M	$ -21.70M	$ -23.28M
Net Non Operating Interest Income Expense	$ 651.00K	$ 651.00K	-	-	-	-
Other Income Expense	$ -1.39M	$ -663.00K	$ -333.00K	$ -160.00K	$ 206.00K	$ 2.75M
Pretax Income	$ -20.18M	$ -18.96M	$ -16.16M	$ -25.15M	$ -21.49M	$ -20.53M
Tax Provision	-	-	-	$ 4.00K	$ 10.00K	$ -124.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -20.18M	$ -18.96M	$ -16.16M	$ -25.16M	$ -21.50M	$ -20.57M
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 10.22M	$ -19.85M	$ -16.72M	$ 25.22M	$ 23.88M	$ 24.51M
Net Income From Continuing And Discontinued Operation	$ -20.18M	$ -18.96M	$ -16.16M	$ -25.16M	$ -21.50M	$ -20.57M
Normalized Income	$ -7.10M	-	-	$ -25.01M	$ -21.55M	$ -22.16M
Interest Expense	-	-	-	-	-	-
EBIT	$ -20.84M	$ -18.96M	$ -16.16M	$ -24.99M	$ -21.70M	$ -23.28M
EBITDA	$ -20.82M	$ -18.95M	$ -16.15M	$ -24.98M	$ -21.68M	$ -23.23M

Currency in USD

Traws Pharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing